Compare BridgeBio Pharma Inc (BBIO) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nokia Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Nokia Corp trades at $9.98 (market cap $51.87B). The key difference: Nokia Corp is far larger — about 3.1× BridgeBio Pharma Inc's market cap, and Nokia Corp pays a 1.79% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NOK | |
|---|---|---|
Market Cap | $16.61B | $51.87B |
Sector | Health | Technology |
52-Week High | $90.17 | $16.83 |
52-Week Low | $47.29 | $4.13 |
Enterprise Value | $18.16B | $49.82B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Nokia (NOK) trades at $9.37, down 0.53% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue for 2025 was $19.89B, with a net income margin of 3.47%. Analyst consensus is 60% buy, supported by strong cash flow from operations of $2.07B in 2025 and a focus on AI and cloud infrastructure growth.
Outlook is cautiously optimistic due to AI demand boosting earnings, but risks include telecom spending volatility and high P/E of 67.5. The stock offers growth potential from AI networking, yet investors face margin pressures and competitive threats in the telecom equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
